GlassScriptPhysician profile
Brooke Esteves
NPI 1265726970
$1,837.13
in general payments reported to CMS, 2019-2025
17 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.35 · 2022: $21.36 · 2023: $518 · 2024: $935 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620 · Education: $97.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.62 |
| Education | $97.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $309.72 | 2023-2025 | Reblozyl, Breyanzi |
| Janssen Biotech, INC. | $234.75 | 2023-2024 | Erleada, Akeega |
| Alafair Biosciences, INC. | $153.64 | 2024 | Versawrap |
| Alexion Pharmaceuticals, INC. | $128.15 | 2024 | |
| Eisai INC. | $125.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $117.75 | 2025 | Datroway |
| Glaxosmithkline, LLC. | $107.27 | 2024 | Zejula |
| Fennec Pharmaceuticals, INC. | $103.08 | 2024 | Pedmark |
| Ipsen Biopharmaceuticals, INC | $98.35 | 2019 | |
| Gilead Sciences, INC. | $96.11 | 2024 | Trodelvy |
| Exelixis INC. | $84.81 | 2023 | Cabometyx |
| Daiichi Sankyo INC. | $81.25 | 2023 | |
| Sanofi-Aventis U.S. LLC | $77.99 | 2023 | |
| Immunogen, INC. | $44.73 | 2023 | Elahere |
| Celgene Corporation | $33.36 | 2025 | Opdualag, Opdivo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $21.36 | 2022 | |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Esteves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.